Loading…
for educational and safety purposes
sci-wiki~$open stack super-synaptogenesis
build the synapse and supply the membrane it is made of; the slowest stack here and the one with the clearest logic
4 items; 4 structures drawn from pubchem.
The argument for this roster is the Kennedy pathway, and it is unusually clean for this field: if you want the brain to make new membrane, supply the two substrates that limit the reaction and add the signal that calls for it. Almost nothing else on this site has that tight a mechanistic story.
⚠️ DIHEXA IS HERE WITH ITS EVIDENCE BASE STATED RATHER THAN GLOSSED. The paper that established its HGF/c-Met mechanism was RETRACTED in 2025 after image manipulation was found, two supporting papers from the same laboratory were retracted alongside it, and the paper that first introduced the compound carries an expression of concern that is still in force. Its animal results are striking and its human evidence does not exist. It stays in this stack because it is the only item that is a growth signal at all, and a reader deciding whether to run it deserves the retraction in the first paragraph rather than in a footnote.
CMS-121 is investigational, from Salk's fisetin programme, and has never been in a human trial.
This stack is a signal plus its raw materials, and that is a genuinely coherent design rather than a themed list.
A new synapse is a physical structure and it is built largely out of phosphatidylcholine. The Wurtman work at MIT is the origin of the pairing here: uridine and choline are the two rate-limiting inputs to the Kennedy pathway that makes phosphatidylcholine, and supplying both together does more than supplying either alone. CDP-choline and uridine monophosphate ARE those two inputs, which is why they appear together in almost every stack that takes membrane synthesis seriously.
Dihexa is the signal that asks for the building to happen; the other two are what it gets built from. CMS-121 is a fisetin derivative from the Salk work, aimed at the protective side rather than the constructive one.
This is the slowest stack on the site and it should be judged in months rather than weeks. CDP-choline is the only item likely to be noticed early, and it is usually noticed as clarity rather than as anything dramatic.
Expecting a first-week effect from a synaptogenesis stack is a category error: the thing being changed takes that long to build even when everything is working.
Two of the four items here have no human safety data of any kind. Dihexa has never been through a registered human trial, and the clinical programme built on its mechanism missed its main Alzheimer's endpoint in 2024. CMS-121 has not been in humans at all. That is the honest headline: half this stack is preclinical, and the half that is not is the half that is a supplement. CDP-choline and uridine are both well tolerated and widely available; if the goal is membrane support alone, they are the two items to run and neither needs a research vendor. Cholinergic overshoot is the one common complaint from the supplement half, presenting as headache or a flat, heavy mood; it responds to lowering the dose rather than to adding anything.
nothing flaggedcurated roster
every pair here reads as compatible on the mechanisms the site holds. that is the absence of a known conflict, not a clearance.
3 of 4 in one basketKimera Chems; Code Sean
4 of 4 priced
1 overlapsame lever, twice
interested in protocols? join the discord; that is where dosing, timing and the practical side get discussed.
the sci-wiki publishes this as a description of what these compounds do together, not as a recommendation to take them. Nothing here is medical advice.